Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Photoallergy Trial of Delgocitinib Cream in Healthy Subjects
NCT04807751Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Mar 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of delgocitinib in atopic dermatitis (AD) (3 arms), sponsored by LEO Pharma. Primary endpoint: Positive skin reaction at 72 hours after irradiation. Started Mar 2021; status: completed.
02
Drugs
delgocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04807751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04807751.